Abstract: In this study, we have defined the molecular mechanisms of 3'-azido-ddG resistance by performing in-depth biochemical analyses of HIV-1 RT containing mutations L74V, F77L, V106I, L214F, R277K, and K476N (SGS3).
Abstract: Pre-steady-state kinetic experiments revealed that the L74V mutation allows RT to effectively discriminate between the natural nucleotide (dGTP) and 3'-azido-ddG-triphosphate (3'-azido-ddGTP).
Abstract: The L74V mutation was found to severely impair RT's ability to excise the chain-terminating 3'-azido-ddG-monophosphate (3'-azido-ddGMP) moiety.
Abstract: We also anal
HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.
Abstract: Virus from four high virus load animals showed several common mutations within RT, including L74V or V75L, G196R, L214F, and K275R.
Result: High VL animals had RT-SHIV with the following RT mutations: either L74V or V75L, which resulted in RT with tandemly repeated leucine or valine at residues 74 and 75 (4 of 4 animals); G196R (3 of 4 animals); L214F (3 of 4 animals); K275R (2 of 4 animals); M357T (1 of
Table: L74V
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
Method: In this study, HIV-2 resistance mutations were identified using the list generated by the 'Collaborative HIV and Anti-HIV Drug Resistance Network', leading to the following mutations in reverse transcriptase - K65R, D67G/N, N69S/T, K70N/R, L74V, V111I, Y115F, M184I/V, Q151M, S215A/C/F/L/Y, K223R; and in protease - V47A, G48V, I50V, I54L/M,
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
PMID: 24633208
2014
The Journal of antimicrobial chemotherapy
Table: L74V
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Discussion: Although Ceccherini-Silberstein reported novel mutations cluster (L74V and H221Y) frequently appears with Y181C and share with it the ability to increase NNRTI resistance , but the idiographic impact and molecular mechanism were unclear.
Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.
PMID: 25397500
2014
Journal of the International AIDS Society
Table: L74V
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
Result: One or more of the non-TAMs, K65R/N, L74V/I, and Y115F were present in 1.4% (n = 3), 26% (n = 16), and 9.2% (n = 8) of patients receiving thymidine-analog, nonthymidine-analog, and both thymidine-analog and nonthymidine-analog regimens.
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
Abstract: The frequency of reduced susceptibility to didanosine was substantial in the abacavir-exposed group (69.1%).This reduced susceptibility was commonly attributed to L74V/I (n = 44) and to a lesser extent K65R (n = 10) mutations.
Result: Resistance to ddI was commonly attributed to the L74V/I mutation (n = 44).
Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
HIV mutation literature information.
PMID: 
2014
Antiviral research
Browser Board
Co-occurred Entities
Filtrator
ViMRT